Intra-tympanic injections in Meniere’s disease

  • Emmanuel Foluwasayo Ologe University of Ilorin, Ilorin, Kwara State
Keywords: Hearing loss, Intra-tympanic injection, Meniere’s disease, Steroids, Vertigo

Abstract

Meniere's disease is a relatively common, sometimes disabling, disease. Pre-referral anti-vertiginous medication is common practice among family physicians. The objective of this review is to present the next level treatment of Meniere disease, beyond conservative management. Major databases such as the Pubmed were searched for recent publications on the management of Meniere’s disease. The findings emphasised that the use of intra-tympanic steroid injections, among other measures, is an extensively researched treatment modality for Meniere’s disease that is unresponsive to conservative management. In conclusion, referring physicians need to go beyond anti-vertiginous medications which family physicians usually prescribe. Aside from other medical treatments, intra-tympanic steroid injection is a simple, safe and reliable treatment option which needs to be further deployed in developing world practice.

References

García MLF, Segura CLS, Lesser JCC, PianeseCP. Endolymphatic Sac Surgery for Meniere’s Disease – Current Opinion and Literature Review. Int Arch Otorhinolaryngol 2017; 21(2): 179-183.

Nakashima T, Pyykko I, Arroll MA, Casselbrant ML, Foster CA, Manzoor NF et al. Meniere’s disease. Nat Rev Dis Primers 2016; 2: 16028.

Simo H, Yang S, Qu W, Preis M, Nazzal M, Baugh R. Meniere’s disease: Importance of socioeconomic and environmental factors. Am J Otolaryngol 2015; 36: 393–398.

Havia M, Kentala E, Pyykko I. Prevalence of Meniere’s disease in general population of Southern Finland. Otolaryngol Head Neck Surg 2005; 133: 762–768.

Tyrrell J, Whinney DJ, Taylor T. The cost of Meniere’s disease: A novel multi-source approach. Ear Hear. 2016; 37: e202–e209.

Ibekwe TS, Fasunla JA, Ibekwe PU, Obasikene GC, Onakoya PA, Nwaorgu OG. Migraine and Meniere's disease: two different phenomena with frequently observed concomitant occurrences. J Natl Med Assoc 2008; 100(3): 334-338.

Ibekwe TS, Ijaduola GT. Meniere's disease: rare or underdiagnosed among Africans. Eur Arch Otorhinolaryngol 2007; 264(12): 1399-1403.

Okafor BC. Incidence of Menière's disease. J Laryngol Otol 1984; 98(8): 775-779.

Somefun OA, Giwa OS, Bamgboye BA, Okeke-Igbokwe II, Azeez AA.Vestibular disorders among adults in a tertiary hospital in Lagos, Nigeria. Eur Arch Otorhinolaryngol 2010; 267(10): 1515-1521.

Yardley L, Dibb B, Osborne G. Factors associated with quality of life in Meniere’s disease. Clin Otolaryngol Allied Sci 2003; 28: 436–441.

Anderson JP, Harris JP. Impact of Meniere’s disease on quality of life. Otol Neurotol 2001; 22: 888–894.

Pullens B, Verschuur HP, van Benthem PP. Surgery for Meniere’s disease. Cochrane Database Syst Rev 2013; 2: CD005395.

Kirby SE, Yardley L. Physical and psychological triggers for attacks in Meniere’s disease: The patient perspective. Psychother Psychosom 2012; 81: 396–398.

Committee on Hearing and Equilibrium. Guidelines for the diagnosis and evaluation of therapy in Menière’s disease. Otolaryngol Head Neck Surg 1995; 113: 181-185.

Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandalà M, et al; Classification Committee of the Barany Society; Japan Society for Equilibrium Research; European Academy of Otology and Neurotology (EAONO); Equilibrium Committee of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS); Korean Balance Society. Diagnostic criteria for Menière's disease. J Vestib Res 2015; 25(1): 1-7.

Frejo L, Soto-Varela A, Santos-Perez S, Aran I,Batuecas-Caletrio A, Perez-Guillen V, et al. On Behalf of the Meniere’s disease Consortium (MeDiC) Clinical Subgroups in Bilateral Meniere’s disease. Frontiers Neurol 2016: 7; 182IN 1-10

Pathak S, Hatam LJ, Bonagura V, Vambutas A. Innate immune recognition ofmolds and homology to the inner ear protein, cochlin, in patients with autoimmune inner ear disease. J Clin Immunol 2013; 33(7): 1204–1215.

Hallpike CS, Cairns H. Observations on the pathology of Meniere’s syndrome. J Laryngol Otol 1938; 53: 625–655.

Foster CA, Breeze RE. Endolymphatic hydrops in Meniere's disease: cause, consequence, or epiphenomenon? Otol Neurotol 2013; 34: 1210–1214.

http://sunnybrook.ca/uploads/1/departments/otolaryngology/untitled.png

Chiarella G, Petrolo C, Cassandro E. The genetics of Meniere’s disease. Appl Clin Genet 2015; 8: 9–17.

Espinosa-Sanchez JM, Lopez-Escamez JA. Menière's disease. Handb Clin Neurol 2016; 137: 257-277.

Teggi R, Zagato L, DelliCarpini S, Citterio L, Cassandro C, Albera R et al. Genetics of ion homeostasis in Meniere’s Disease. Eur Arch Otorhinolaryngol 2017; 274(2): 757-763.

Pan T, Zhao Y, Ding YJ, Lu ZY, Ma FR. The pilot study of type I allergic reaction in Meniere's disease patients. Zhonghua Er Bi Yan Hou Tou Jing WaiKe Za Zhi 2017; 52(2): 89-92.

Schmidt W, Sarran C, Ronan N, Barrett G, Whinney DJ, Fleming LE, et al. The Weather and Ménière’s Disease: A Longitudinal Analysis in the UK. Otol Neurotol 2017; 38(2): 225–233.

van den Burg EL, van Hoof M, Postma AA, Janssen AML, Stokroos RJ, Kingma H, et al. An exploratory study to detect Meniere’s disease in Conventional MRI Scans using Radiomics. Frontiers Neurol 2016; 7: 1901-1909.

Yoshida T, Sugimoto S, Teranishi M, Otake H, Yamazaki M, Naganawa S, et al. Imaging of the endolymphatic space in patients with Meniere’s disease. Auris Nasus Larynx 2017; S0385-8146(17)30142-6.

Farhood Z, Lambert PR. The physiologic role of corticosteroids in Ménière's disease. Am J Otolaryngol 2016; 37(5): 455-458.

Wick CC, Manzoor NF, McKenna C, Semaan MT, Megerian CA. Long-term outcomes of endolymphatic sac shunting with local steroids for Meniere's disease. Am J Otolaryngol 2017; S0196-0709(17)30017-0.

Zhang D, Fan Z, Han Y, Lv Y, Li Y, Wang H. Triple semicircular canal plugging: a novel modality for the treatment of intractable Meniere's disease. Acta Otolaryngol 2016; 136(12): 1230-1235.

Zhang DG, Xu L, Han YC, Lyu YF, Luo JF, Li YW, et al. Simultaneous triple semicircular canal plugging and cochlear implantation in advanced Meniere's disease. Zhonghua Er Bi Yan HouTou Jing WaiKe Za Zhi 2017; 52(1): 25-30.

Alarcón AV, Hidalgo LOV, Arévalo RJ, Diaz MP. Labyrinthectomy and Vestibular Neurectomy for Intractable Vertiginous Symptoms. Int Arch Otorhinolaryngol 2017; 21: 184–190.

Silverstein H, Norrell H, Smouha E, Jones R. Combined retrolabretrosigmoid vestibular neurectomy. An evolution in approach. Am J Otol 1989; 10(03): 166–169.

Setty P, Babu S, LaRouere MJ, Pieper DR.Fully Endoscopic Retrosigmoid Vestibular Nerve Section for Refractory Meniere Disease. J Neurol Surg B Skull Base 2016; 77(4): 341-349.

Canzi P, Manfrin M, Perotti M, Aprile F, Quaglieri S, Rebecchi E, et al. Translabyrinthine vestibular neurectomy and simultaneous cochlear implant for Meniere’s disease. Acta Neurochir (Wien) 2017; 159(1): 123-130.

Sargent EW, Liao E, Gonda RL Jr. Cochlear patency after transmastoid labyrinthectomy for Meniere’s syndrome. Otol Neurotol 2016; 37(07): 937–939.

Mukherjee P, Eykamp K, Brown D, Curthoys I, Flanagan S, Biggs N, et al.Cochlear Implantation in Meniere’s Disease With and Without Labyrinthectomy. Otol Neurotol 2017; 38(2): 192-198.

Liu B, Zhang S, Leng Y, Zhou R, Liu J, Kong W. Intratympanic injection in delayed endolymphatic hydrops. Acta Otolaryngol 2015; 135: 1016–1021.

Ferri E,Frisina A,Fasson AC, Armato E, Spinato G, Amadori M. Clinical Study Intratympanic Steroid Treatment for Idiopathic Sudden Sensorineural Hearing Loss after Failure of Intravenous Therapy. ISRN Otolaryngol 2012, ID 647271: 1-6.

http://www.drmkotb.com/myimages/Intratympanic%20injection.jpg

Liu B, Leng YM, Shi H, Zhou RH, Liu JJ, Zhang S, et al. Modified titration intratympanic gentamicin injection for unilateral intractable Meniere’s disease. J Huazhong Univ Sci Technol Med Sci 2015; 35: 747–751.

Liu B, Leng Y, Zhou R, Liu J, Liu D, Zhang, S et al. Intratympanic steroids injection is effective for the treatment of drop attacks with Meniere’s disease and delayed endolymphatic hydrops: A retrospective study. Medicine 2016; 95: 52 1-4.

Patel M, Agarwal K, Arshad Q, Hariri M, Rea P, Seemungal BM, et al. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness trial. Lancet. 2016; 388(10061): 2753-2762.

Topf MC, Hsu DW, Adams DR, Zhan T, Pelosi S, Willcox TO, et al. Rate of tympanic membrane perforation after intratympanic steroid injection. Am J Otolaryngol 2017; 38(1): 21-25.

Lambert PR, Carey J, Mikulec AA, LeBel C. Otonomy Ménièreʼs Study Group. Intratympanic Sustained-Exposure Dexamethasone Thermosensitive Gel for Symptoms of Meniere’s Disease Randomized Phase 2b Safety and Efficacy Trial. Otol Neurotol 2016; 37(10): 1669-1676.

Vlastarakos PV, Iacovou E, Nikolopoulos TP. Is gentamycin delivery via sustained-release vehicles a safe and effective treatment for refractory Meniere's disease? A critical analysis of published interventional studies. Eur Arch Otorhinolaryngol 2017; 274(3): 1309-1315.

Atrache A, Attrache N, Krstulovic C, Pérez Guillen V, Morera Pérez C, Pérez Garrigues H.Response Over Time of Vertigo Spells to Intratympanic Dexamethasone Treatment in Meniere's Disease Patients. J Int Adv Otol 2016; 12(1): 92-97.

Albu S, Nagy A, Doros C, Marceanu L, Cozma S, Musat G, et al. Treatment of Meniere's disease with intratympanic dexamethasone plus high dosage of betahistine. Am J Otolaryngol 2016; 37(3): 225-230.

Sam G, Chung DW, van der Hoeven R, Verweij S, Becker M. The effect of intratympanic gentamicin for treatment of Ménière's disease on lower frequency hearing. Int J Clin Pharm 2016; 38(4): 780-783.

Celis-Aguilar E, Hinojosa-González R, Vales-Hidalgo O, Coutinho-Toledo H. Refractory episodic vertigo: role of intratympanic gentamicin and vestibular evoked myogenic potentials. Braz J Otorhinolaryngol 2016; 82(6): 668-673.

Olusesi AD, Hassan SB, Oyeyipo Y, Ukwuije UC, Oyeniran O. Chemical labyrinthectomy for the worse ear of adult Nigerians with bilateral Meniere's disease: preliminary report of treatment outcomes. Eur Arch Otorhinolaryngol 2015; 272(6): 1383-1387.

Published
2017-06-12
Section
Articles